Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01495104
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
Phase 2
Completed
- Conditions
- Hypertension, Glaucoma, Open-Angle
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT01493271
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
Phase 1
Completed
- Conditions
- Breast Cancer, Colorectal Cancer
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT01493336
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 258
- Registration Number
- NCT01491737
- Locations
- 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇺🇸Washington University School of Medicine; Internal Medicine - Renal, Saint Louis, Missouri, United States
🇺🇸Ironwood Cancer TX & Rsch Ctrs, Chandler, Arizona, United States
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 217
- Registration Number
- NCT01488331
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 327
- Registration Number
- NCT01488162
An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT01484483
- Locations
- 🇰🇪
University of Nairobi School of Medicine; Internal Medicine and Therapeutics, Nairobi, Kenya
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT01483742
Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: Accu-Chek DiaPort
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT01483352
A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT01483729
© Copyright 2025. All Rights Reserved by MedPath